Shares of Molecular Templates (MTEM) have risen by 157% since my 2018 recommendation and by 127% since my September 2019 update. In the latter, I highlighted an agreement with Takeda to develop CD38-targeted engineered toxin bodies (ETBs) and potential advantages over approved drug Darzalex (which did nearly $3 billion in 2019 sales).
With a couple presentations at virtual investor conferences coming up this month, dilutive financing out of the way, multiple assets moving forward in the clinic and the stock pulling back below its 50 day moving average, I'm keen to